Erasmia Psimenou

2.2k total citations
69 papers, 1.5k citations indexed

About

Erasmia Psimenou is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Erasmia Psimenou has authored 69 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 34 papers in Hematology and 19 papers in Oncology. Recurrent topics in Erasmia Psimenou's work include Amyloidosis: Diagnosis, Treatment, Outcomes (32 papers), Multiple Myeloma Research and Treatments (28 papers) and Protein Degradation and Inhibitors (7 papers). Erasmia Psimenou is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (32 papers), Multiple Myeloma Research and Treatments (28 papers) and Protein Degradation and Inhibitors (7 papers). Erasmia Psimenou collaborates with scholars based in Greece, United Kingdom and Italy. Erasmia Psimenou's co-authors include Meletios Α. Dimopoulos, Efstathios Kastritis, Μαρία Ρούσσου, Evangelos Terpos, Magdalini Migkou, Maria Gavriatopoulou, Irini Grapsa, Evangelos Eleutherakis‐Papaiakovou, Despina Fotiou and C. Matsouka and has published in prestigious journals such as Blood, Kidney International and American Journal of Kidney Diseases.

In The Last Decade

Erasmia Psimenou

65 papers receiving 1.4k citations

Peers

Erasmia Psimenou
Gerald B. Appel United States
Haruhiko Ninomiya Japan
Evangelos Eleutherakis‐Papaiakovou Greece
G. Bánfi Italy
Marta Krejčí Czechia
Dorottya Csuka Hungary
Arnaud Lionet France
Eileen M. Boyle United States
Robert F. Cornell United States
Jorge Vela‐Ojeda Mexico
Gerald B. Appel United States
Erasmia Psimenou
Citations per year, relative to Erasmia Psimenou Erasmia Psimenou (= 1×) peers Gerald B. Appel

Countries citing papers authored by Erasmia Psimenou

Since Specialization
Citations

This map shows the geographic impact of Erasmia Psimenou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erasmia Psimenou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erasmia Psimenou more than expected).

Fields of papers citing papers by Erasmia Psimenou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erasmia Psimenou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erasmia Psimenou. The network helps show where Erasmia Psimenou may publish in the future.

Co-authorship network of co-authors of Erasmia Psimenou

This figure shows the co-authorship network connecting the top 25 collaborators of Erasmia Psimenou. A scholar is included among the top collaborators of Erasmia Psimenou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erasmia Psimenou. Erasmia Psimenou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fotiou, Despina, Foteini Theodorakakou, Ioannis Ntanasis‐Stathopoulos, et al.. (2025). Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis. Clinical Lymphoma Myeloma & Leukemia. 25(7). 532–538.
2.
Dimopoulos, Meletios Α., Ioannis Ntanasis‐Stathopoulos, Despina Fotiou, et al.. (2025). Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution. American Journal of Hematology. 100(10). 1747–1759. 2 indexed citations
3.
Fotiou, Despina, Foteini Theodorakakou, Panagiota Nikolaou, et al.. (2024). TEMPI syndrome: difficult to diagnose, “easy” to treat?. Annals of Hematology. 103(9). 3787–3793.
4.
Bampatsias, Dimitrios, Dimitrios S. Karagiannakis, Eleni Korompoki, et al.. (2023). SARS-CoV-2 infection-related deregulation of blood lipids in a patient with -/-LDLR familial homozygous hypercholesterolemia: A case report. Journal of clinical lipidology. 17(2). 219–224. 1 indexed citations
5.
Vakrakou, Aigli G., Maria‐Eleftheria Evangelopoulos, John S. Tzartos, et al.. (2021). Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases. Therapeutic Advances in Neurological Disorders. 14. 4203287591–4203287591. 12 indexed citations
6.
Tzartos, John S., Serena Valsami, Erasmia Psimenou, et al.. (2020). Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion. Neurology Neuroimmunology & Neuroinflammation. 7(3). 8 indexed citations
7.
Kastritis, Efstathios, Maria Gavriatopoulou, Μαρία Ρούσσου, et al.. (2017). Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. American Journal of Hematology. 92(7). 632–639. 45 indexed citations
8.
Dimopoulos, Meletios Α., Μαρία Ρούσσου, Μαρία Γκοτζαμανίδου, et al.. (2012). The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 27(2). 423–429. 106 indexed citations
9.
Tsagalis, George, et al.. (2010). Combination Treatment With Plasmapheresis and Rituximab for Recurrent Focal Segmental Glomerulosclerosis After Renal Transplantation. Artificial Organs. 35(4). 420–425. 43 indexed citations
10.
Ρούσσου, Μαρία, Efstathios Kastritis, Dimitrios Christoulas, et al.. (2010). Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leukemia Research. 34(10). 1395–1397. 53 indexed citations
11.
Tsagalis, George, et al.. (2009). Rapamycin for Focal Segmental Glomerulosclerosis: A Report of 3 Cases. American Journal of Kidney Diseases. 54(2). 340–344. 13 indexed citations
12.
Bamias, Aristotelis, et al.. (2009). Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. Clinical Nephrology. 72(7). 73–78. 10 indexed citations
13.
14.
Kastritis, Efstathios, Αchilles Anagnostopoulos, Μαρία Ρούσσου, et al.. (2007). Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 92(4). 546–549. 113 indexed citations
15.
Delladetsima, Ioanna, Mina Psichοgiou, Vana Sypsa, et al.. (2006). The Course of Hepatitis C Virus Infection in Pretransplantation Anti–Hepatitis C Virus–Negative Renal Transplant Recipients: A Retrospective Follow-Up Study. American Journal of Kidney Diseases. 47(2). 309–316. 23 indexed citations
16.
17.
Zavos, G., Maria Gazouli, Erasmia Psimenou, et al.. (2004). Polyomavirus BK infection in Greek renal transplant recipients. Transplantation Proceedings. 36(5). 1413–1414. 10 indexed citations
18.
Kingdon, Edward, A. McLean, Erasmia Psimenou, et al.. (2001). The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus. 10(9). 606–611. 68 indexed citations
19.
Varghese, Zac, Ray Fernando, Erasmia Psimenou, et al.. (1999). Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients. Kidney International. 56. S137–S140. 26 indexed citations
20.
Varghese, Z., Ray Fernando, Erasmia Psimenou, et al.. (1998). Oxidizability of low-density lipoproteins from neoral and tacrolimus-treated renal transplant patients. Transplantation Proceedings. 30(5). 2043–2046. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerald B. Appel Breakdown of academic impact, for papers by Haruhiko Ninomiya Breakdown of academic impact, for papers by Evangelos Eleutherakis‐Papaiakovou Breakdown of academic impact, for papers by G. Bánfi Breakdown of academic impact, for papers by Marta Krejčí Breakdown of academic impact, for papers by Dorottya Csuka Breakdown of academic impact, for papers by Arnaud Lionet Breakdown of academic impact, for papers by Eileen M. Boyle Breakdown of academic impact, for papers by Robert F. Cornell Breakdown of academic impact, for papers by Jorge Vela‐Ojeda
Rankless by CCL
2026